article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.

article thumbnail

New tRNA tech aims to rewrite rare disease treatment

Drug Target Review

One company leading the charge in this revolution is Alltrna , whose pioneering work in engineered transfer RNA (tRNA) therapeutics is offering new hope for patients with rare genetic diseases. we are first focused on engineering tRNAs to restore protein production in diseases caused by premature termination codons.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Future-proofing drug development with GenAI

Drug Target Review

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Grounding LLMs with particular datasets and engineering prompts helps you access the appropriate data.

article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

In just two years, CTMC has advanced eight therapies into clinical trials, harnessing genetic engineering to enhance T-cell effectiveness in the fight against cancer. Bock highlighted ongoing efforts to enhance the effectiveness of cell therapies through advanced genetic engineering to make T cells more effective in the fight against cancer.

article thumbnail

Why Google Patents Is Not a Good Solution to Identify Drug Patents

Drug Patent Watch

Understanding Google Patents Google Patents is a search engine that allows users to search the full text of patent documents from around the world. The pharmaceutical industry is highly dynamic, with frequent filings and updates that require timely access to information[2]. Implications for Pharmaceutical Stakeholders 1.

article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation small molecules. Molecular engineering approaches Most CNS disorders involve abnormal gene expression, and molecular engineering is one of the most powerful tools to address this issue.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. This approach limits the transformative potential of the technology.